AXIM Biotechnologies, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
Notes Tables
Notes Details

NOTE 4: SIGNIFICANT ACCOUNTING POLICIES: Intangible Assets (Policies)

NOTE 4: SIGNIFICANT ACCOUNTING POLICIES: Intangible Assets (Policies)	6 Months Ended
Jun. 30, 2019
Policies
Intangible Assets	Intangible Assets As required by generally accepted accounting principles, trademarks and patents are not amortized since they have an indefinite life. Instead, they are tested annually for impairment. Intangible assets as of June 30, 2019 amounted to $50,534 net of accumulated impairment losses of $664,898.

NOTE 4: SIGNIFICANT ACCOUNTING POLICIES: Intangible Assets (Policies)

6 Months Ended

Jun. 30, 2019

Policies

Intangible Assets

Intangible Assets

As required by generally accepted accounting principles, trademarks and patents are not amortized since they have an indefinite life. Instead, they are tested annually for impairment. Intangible assets as of June 30, 2019 amounted to $50,534 net of accumulated impairment losses of $664,898.